Research Highlights:
- Health screening and genetic tests might identify more than 1 million U.S. adults who have familial hypercholesterolemia, a common genetic disorder that causes elevated bad cholesterol levels, which may lead to premature cardiovascular disease.
- Identifying familial hypercholesterolemia early in adulthood creates an opportunity for early treatment aimed at preventing heart attack and death, according to a new study.
Embargoed until 4 a.m. CT/5 a.m. ET Wednesday, May 18, 2022
DALLAS, May 18, 2022 — Health screening and genetic tests might identify more than 1 million U.S. adults who carry a gene for familial hypercholesterolemia, a common genetic disorder that causes elevated low-density lipoprotein (LDL) cholesterol, known as “bad cholesterol,” which may lead to premature heart attack or death, according to new research published today in the Journal of the American Heart Association, an open access, peer-reviewed journal of the American Heart Association.
According to the American Heart Association, familial hypercholesterolemia is an inherited genetic disorder that affects how the body recycles bad cholesterol. As a result, LDL levels in the blood remain very high; in severe cases, levels can reach above 190 milligrams per deciliter (mg/dL) of blood in adults. The desirable level for LDL is less than 100 mg/dL. However, total blood cholesterol levels should be considered in the context of other known cardiovascular disease risk factors.
An estimated 1 in 250 people in the U.S. may carry at least one gene for familial hypercholesterolemia. Among the people who have one familial hypercholesterolemia gene, the average age for a first heart attack if the condition is not treated is 50 years for men and 60 years for women, while the average age for a first heart attack in the general population is 66 years for men and 72 years for women. A much smaller number of people may inherit two genes for familial hypercholesterolemia (one from each parent), and they have more severe complications, including far higher bad cholesterol and heart disease beginning in childhood or adolescence.
“Currently, most individuals aren’t diagnosed with familial hypercholesterolemia until they are in their 50s. If a young adult is identified to have familial hypercholesterolemia, they would likely benefit from earlier and more aggressive treatment to prevent heart attack and stroke,” said study lead author Brandon K. Bellows, Pharm.D., M.S., an assistant professor of medical sciences at Columbia University in New York City.
The American Heart Association recommends that all adults ages 20 or older have their cholesterol and other traditional heart risk factors checked every four to six years, if risk remains low. Familial hypercholesterolemia screening is not standard and requires the accurate collection of additional clinical information or diagnostic genetic testing. Genetic testing is available; however, it may not be affordable for many people when not covered by health insurance. A 2020 American Heart Association scientific statement suggests that genetic testing for cardiovascular diseases should typically be reserved for people who have a confirmed or suspected diagnosis of a condition and for those with a known disease-causing gene variant in their family.
In this study, researchers estimated how many people with familial hypercholesterolemia could be identified if all adults were screened using clinical factors, such as cholesterol levels and the presence of early heart disease in an individual or close family member (parent, sibling or child), both with and without genetic testing.
The researchers obtained clinical information and genetic test results for about 50,000 adults, ages 40-69, from the UK Biobank collected between 2006 and 2010. From this, they were able to estimate the probability each individual had of carrying a familial hypercholesterolemia genetic variant based on their clinical information. To estimate familial hypercholesterolemia genetic variants in a U.S. population that did not have genetic test results, the researchers applied the relationships observed in the UK Biobank to a dataset of almost 40,000 adults (ages 20 years or older) from the National Health and Nutrition Examination Survey (NHANES).
The UK Biobank is a large biomedical database that includes genetic and health information on a half million people living in the United Kingdom. NHANES is a nationally representative sample of U.S. adults including people from diverse racial and ethnic backgrounds collected from 1999-2000 to 2015-2016.
To evaluate the performance of clinical criteria in the U.S. data, the researchers used the Dutch Lipid Clinic Network criteria to classify people with definite or probable familial hypercholesterolemia based on a scoring system that combined a personal history of early heart disease; family history of early heart attack or heart-related chest pain (angina) in a sibling, parent, or child; and high untreated bad cholesterol levels, with more points for higher cholesterol levels.
Using this multi-step approach, the results estimated:
- The clinical criteria alone identified 3.7 familial hypercholesterolemia cases per 1,000 adults screened, while genetic testing alone identified 3.8 familial hypercholesterolemia cases per 1,000 adults screened.
- When both clinical criteria and genetic testing were combined, 6.6 familial hypercholesterolemia cases per 1,000 adults screened were identified.
- In young adults ages 20-39 years, clinical criteria alone identified 1.3 familial hypercholesterolemia cases per 1,000 individuals screened, rising to 4.2 per 1,000 when genetic testing was also included.
“We need to do more to support familial hypercholesterolemia screening programs,” said Bellows. “Screening for familial hypercholesterolemia should include clinical factors and genetic testing. Individuals with high cholesterol levels or with a family member that had a heart attack at a young age should undergo genetic testing for familial hypercholesterolemia. Early diagnosis and treatment of familial hypercholesterolemia are the best ways to reduce the risk of early heart attack or stroke.”
The higher proportion of people identified through genetic testing added to clinical criteria indicates that many people with a genetic mutation may not exhibit the typical clinical picture at the time of screening. “This has been seen in other studies. Universal screening programs with genetic testing may be the best way to identify these individuals. However, this may be impractical and, thus, targeted screening to specific groups such as young adults may allow for earlier identification and treatment of familial hypercholesterolemia,” Bellows said.
A limitation of the study includes that the U.K. biobank dataset was a population of older adults (ages 40-69 years) and the majority of whom self-identified as white. Therefore, the analysis of the UK Biobank dataset may not be generalizable to diverse or younger populations.
The researchers are conducting follow-up studies to answer questions about the most useful and cost-effective strategies for familial hypercholesterolemia screening, such as the best age to start screening and whether there is a difference in the number of heart attacks and strokes based on screening method, for example universal screening vs. close family members with familial hypercholesterolemia.
Co-authors are Amit V. Khera, M.D., M.Sc.; Yiyi Zhang, Ph.D.; Natalia Ruiz-Negrón, Pharm.D.; Henry M. Stoddard, M.P.H.; John B. Wong, M.D.; Dhruv S. Kazi, M.D., M.Sc., M.S.; Sarah D. de Ferranti, M.D., M.P.H.; and Andrew E. Moran, M.D., M.P.H. Authors’ disclosures are listed in the manuscript.
The analysis was supported by the National Human Genome Research Institute and the National Heart, Lung, and Blood Institute, divisions of the National Institutes of Health.
Studies published in the American Heart Association’s scientific journals are peer-reviewed. The statements and conclusions in each manuscript are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers and the Association’s overall financial information are available here.
Additional Resources:
About the American Heart Association
The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.
###
For Media Inquiries and AHA/ASA Expert Perspective: 214-706-1173
Karen Astle: 214-706-1392; karen.astle@heart.org
For Public Inquiries: 1-800-AHA-USA1 (242-8721)
heart.org and stroke.org
Leave a Reply